AC
CNSP icon

Armistice Capital’s CNS Pharmaceuticals CNSP Stock Holding History

Armistice Capital’s Portfolio CNSP Stock Details CNSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-33,833
Closed -$335K – 349
2025
Q2 		$335K Buy
+33,833
New +$423K 0.01% 170
2024
Q2 		– Sell
-16
Closed -$171K – 283
2024
Q1 		$171K Buy
16
+12
+300% +$174K ﹤0.01% 297
2023
Q4 		$155K Buy
+4
New +$209K ﹤0.01% 247
2023
Q2 		– Sell
-4
Closed -$124K – 233
2023
Q1 		$124K Hold
4
– – ﹤0.01% 193
2022
Q4 		$320K Buy
+4
New +$550K 0.01% 148

Other funds holding CNSP

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Barrett & Company Providence, Rhode Island $357M AUM 22.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

Armistice Capital's CNSP Position: Q3 2025 in Review

Armistice Capital sold out of CNS Pharmaceuticals (CNSP) in Q3 2025, closing a stake of 33,833 shares — an estimated $335K sold.

Armistice Capital first reported a position in CNSP in Q4 2022 and held it in 5 quarters. The position peaked at $335K in Q2 2025. 8 funds tracked by Wall St. Rank hold CNSP as of Q3 2025.

  • Armistice Capital reported no remaining CNS Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Armistice Capital sold 33,833 CNS Pharmaceuticals shares in Q3 2025, an estimated $335K.
  • Armistice Capital first reported a position in CNS Pharmaceuticals in Q4 2022 and held it in 5 quarters.
  • Armistice Capital's CNS Pharmaceuticals position peaked at $335K in Q2 2025.
  • 8 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q3 2025.

Based on Armistice Capital's 13F filing for Q3 2025, filed 17 Nov 2025.